跳至主要内容
临床试验/NCT01069159
NCT01069159Unknown不适用

Propranolol Treatment of Traumatic Memories (PTTM)

Mela, Mansfield, M.D.1 个研究点 分布在 1 个国家目标入组 66 人开始时间: 2010年2月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
发起方
入组人数
66
试验地点
1
主要终点
The primary endpoint will be changes between the pretreatment and posttreatment scores in the Clinician Assessment Posttraumatic Scale (CAPS), Impact of Event Scale (IES) and Traumatic Memory Description Measure (TMDM) instruments.

研究概览

简要总结

This study will compare the responses of subjects with traumatic memories of varying vintages to either propranolol or placebo in a double-blind setting. It is hypothesized that those subjects who receive propranolol will experience less emotional distress when the memory is subsequently reactivated and less spontaneous re-experiences.

详细描述

Traumatic memories are responsible for significant emotional distress and disability. They are a cardinal feature of Posttraumatic Stress Disorder (PTSD). Re-experiencing the original traumatic event in a number of different ways (e.g. nightmares, intrusive recollections and dissociative flashbacks) is accompanied by distressing symptoms. The reconsolidation theory of memory proposes that when long-term memories are reactivated, they remain labile for several hours before conversion back to long-term memory. During this period they are susceptible to amnestic agents, like propranolol.

Propranolol Hydrochloride will be compared to placebo in subjects who have emotional distress associated with re-experiences of traumatic events, whether in the context of PTSD or not. Two doses of propranolol or two doses of placebo will be given at the first visit.

The objective of the trial is to determine the effectiveness of brief treatment with propranolol on subjects with traumatic memories and associated symptoms. The research hypothesis is that propranolol will be more effective than placebo, as determined by the measures used, and that this positive outcome will support the reconsolidation theory of memory.

The subjects will undergo clinician rated assessments/scales to determine the presence of pre-treatment mental disorders. Subjects will complete self-rating measures/scales to determine the impact of the traumatic experience. Blood pressure and pulse rates will also be recorded.

Post-treatment outcomes using the same instruments to determine changes at four weeks will be recorded. The differences will be compared and subjected to statistical analysis.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male or female adults between 18 and 70 years of age
  • A traumatic memory, as an isolated symptom or in the context of Post-traumatic Stress Disorder

排除标准

  • Pregnancy
  • Breastfeeding
  • Current treatment with either a beta-blocker or a corticosteroid medicine
  • Medical contraindications, as outlined in the Compendium of Pharmaceutical and Specialties and the Product Monograph
  • Subjects who want to retain every aspect of their memory for the traumatic event, as some memory could be lost

研究组 & 干预措施

Propranolol

Active Comparator

The protocol of the study requires that two doses of propranolol (regular propranolol 40 mg followed two hours later by long-acting propranolol 60 mg) be given at the first visit, to be taken within one hour of the reactivation of the traumatic memory. Half of the subjects (33) will be randomized to receive propranolol.

干预措施: Propranolol Hydrochloride (Drug)

Placebo

Placebo Comparator

The protocol of the study requires that two doses of placebo be given at the first visit, to be taken within one hour of the reactivation of the traumatic memory. Half of the subjects (33) will be randomized to receive placebo.

干预措施: Placebo (Drug)

结局指标

主要结局

The primary endpoint will be changes between the pretreatment and posttreatment scores in the Clinician Assessment Posttraumatic Scale (CAPS), Impact of Event Scale (IES) and Traumatic Memory Description Measure (TMDM) instruments.

时间窗: Visit 2 (Week 4)

次要结局

  • The secondary endpoint will be changes between the treatment and posttreatment score in the other scales used - MINI, ZAS, ZDS and NIHS.(Visit 2 (Week 4))

研究者

发起方
Mela, Mansfield, M.D.
申办方类型
Indiv

研究点 (1)

Loading locations...

相似试验

Propranolol Treatment of Traumatic Memories (PTTM) | 临床试验